Georgetown site will be first to offer all forms of microtracer and microdose investigations.
Xceleron’s existing investors Albion Ventures and Solon Ventures have ploughed another $2.4 million into the firm to fund its relocation from the U.K. into a new, custom-build facility in Germantown, MD. The new facility is expected to be fully operational by the end of March and will house the latest LC-MS/MS technology. The move will involve relocating senior analytical staff to the new facility and hiring additional staff.
Xceleron specializes in the provision of bioanalytical accelerator mass spectrometry (AMS) services for drug development including pharmacokinetic and metabolism studies in clinical trials up to Phase II/III. The firm says the addition of the latest LC-MS/MS platforms means its Germantown laboratory will be the first to offer all forms of microtracer and microdose investigations under one roof.
“The combined ruggedness of AMS and the specificity of the most sensitive LC-MS/MS will enable a highly cost-effective and safe bridge from discovery to the clinic,” remarks Stuart Best, vp for analytical operations at Xceleron.